The Claim
Semaglutide reduces the incidence of major adverse cardiovascular events by 20% in individuals with obesity and established cardiovascular disease who do not have type 2 diabetes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you're obese and have heart disease but not diabetes, taking semaglutide might lower your chances of having a serious heart problem by 20%.
See the scientific wording
Semaglutide reduces the incidence of major adverse cardiovascular events by 20% in individuals with obesity and established cardiovascular disease but without type 2 diabetes.
What the research says
4 studiesStudy: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The study tested semaglutide in people with obesity and heart disease but no diabetes, and found it reduced heart problems by 20%, just like the claim says.
Study: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study looked at kidney health but also confirmed that semaglutide reduced heart problems by 20% in people with obesity and heart disease who don’t have diabetes, which is exactly what the claim says.
Study: Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
The study looks at semaglutide in people with obesity and heart disease but no diabetes, and says it helps reduce serious heart problems, which matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 4 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.